DK1440709T3 - Kombinationer, der omfatter cGMP PDE5 inhibitorer - Google Patents

Kombinationer, der omfatter cGMP PDE5 inhibitorer

Info

Publication number
DK1440709T3
DK1440709T3 DK04010436T DK04010436T DK1440709T3 DK 1440709 T3 DK1440709 T3 DK 1440709T3 DK 04010436 T DK04010436 T DK 04010436T DK 04010436 T DK04010436 T DK 04010436T DK 1440709 T3 DK1440709 T3 DK 1440709T3
Authority
DK
Denmark
Prior art keywords
combinations
pde5 inhibitors
cgmp pde5
cgmp
inhibitors
Prior art date
Application number
DK04010436T
Other languages
Danish (da)
English (en)
Inventor
Eliot Richard Forster
Nandan Parmanand Koppiker
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9924958.3A external-priority patent/GB9924958D0/en
Priority claimed from GB0021520A external-priority patent/GB0021520D0/en
Application filed by Pfizer filed Critical Pfizer
Application granted granted Critical
Publication of DK1440709T3 publication Critical patent/DK1440709T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DK04010436T 1999-10-21 2000-10-17 Kombinationer, der omfatter cGMP PDE5 inhibitorer DK1440709T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9924958.3A GB9924958D0 (en) 1999-10-21 1999-10-21 Treatment of neuropathy
GB0021520A GB0021520D0 (en) 2000-09-01 2000-09-01 Treatment of neuropathy

Publications (1)

Publication Number Publication Date
DK1440709T3 true DK1440709T3 (da) 2008-03-17

Family

ID=26244947

Family Applications (1)

Application Number Title Priority Date Filing Date
DK04010436T DK1440709T3 (da) 1999-10-21 2000-10-17 Kombinationer, der omfatter cGMP PDE5 inhibitorer

Country Status (16)

Country Link
US (2) US20030162782A1 (fr)
EP (2) EP1129706A3 (fr)
JP (2) JP2001122803A (fr)
KR (1) KR20010051181A (fr)
AT (1) ATE380049T1 (fr)
AU (1) AU781550B2 (fr)
CA (1) CA2323839C (fr)
CO (1) CO5271711A1 (fr)
CY (1) CY1107285T1 (fr)
DE (1) DE60037347T2 (fr)
DK (1) DK1440709T3 (fr)
ES (1) ES2295726T3 (fr)
HU (1) HUP0004120A3 (fr)
IL (2) IL152925A (fr)
PE (1) PE20010754A1 (fr)
PT (1) PT1440709E (fr)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1365806A2 (fr) * 2000-04-19 2003-12-03 Johns Hopkins University Utilzation d'activators de no pour le traitement et la prevention des troubles gastrointestinaux
FR2809623B1 (fr) * 2000-06-05 2003-09-05 Sanjuan Benito Arranz Dans le traitement des maladies neurodegeneratives : (notamment alzheimer et parkinson), utilisation pour un medicament : du sildenafil (ou de ses derives)
DE10135815A1 (de) * 2001-07-23 2003-02-06 Bayer Ag Verwendung von 2-Alkoxyphenyl-substituierten Imidazotriazinonen
WO2003020702A2 (fr) 2001-08-31 2003-03-13 The Rockefeller University Activite de phosphodiesterase et regulation de la signalisation a mediation par phosphodiesterase 1-b dans le cerveau
GB0129274D0 (en) * 2001-12-06 2002-01-23 Pfizer Ltd Novel kit
CA2471147C (fr) 2002-01-04 2010-08-10 Henry Ford Health System Donneurs de monoxyde d'azote pour le traitement de maladies et de blessures
US7419981B2 (en) 2002-08-15 2008-09-02 Pfizer Inc. Synergistic combinations of an alpha-2-delta ligand and a cGMP phosphodieterse 5 inhibitor
GB0219024D0 (en) * 2002-08-15 2002-09-25 Pfizer Ltd Synergistic combinations
US7659305B2 (en) 2002-10-31 2010-02-09 Pfizer Inc. Therapeutic proline derivatives
RU2331438C2 (ru) * 2002-12-13 2008-08-20 Уорнер-Ламберт Компани Ллс Альфа-2-дельта лиганд для лечения симптомов нижних мочевыводящих путей
NZ541188A (en) 2003-04-23 2008-01-31 Japan Tobacco Inc calcium receptor antagonists
DE10325813B4 (de) * 2003-06-06 2007-12-20 Universitätsklinikum Freiburg Prophylaxe und/oder Therapie bei der portalen Hypertonie
DE602005017135D1 (de) * 2004-03-05 2009-11-26 Nycomed Gmbh Neue verwendung von pde5-hemmern
WO2006133261A2 (fr) * 2005-06-06 2006-12-14 Intra-Cellular Therapies, Inc. Composes organiques
EP1919287A4 (fr) * 2005-08-23 2010-04-28 Intra Cellular Therapies Inc Composés organiques pour traiter un signald'activité réduit du récepteur de la dopamine
JP5453086B2 (ja) * 2006-06-06 2014-03-26 イントラ−セルラー・セラピーズ・インコーポレイテッド 有機化合物
ES2411604T3 (es) * 2006-11-13 2013-07-05 Intra-Cellular Therapies, Inc. Compuestos orgánicos
US9006258B2 (en) 2006-12-05 2015-04-14 Intra-Cellular Therapies, Inc. Method of treating female sexual dysfunction with a PDE1 inhibitor
US7638541B2 (en) 2006-12-28 2009-12-29 Metabolex Inc. 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine
WO2008131256A1 (fr) * 2007-04-19 2008-10-30 Trinity Laboratories Inc. Traitements améliorés pour une éjaculation précoce chez les humains
CN101754962B (zh) 2007-07-19 2013-12-25 赛马拜制药公司 作为rup3或gpr119受体的激动剂治疗糖尿病和代谢性病症的n-氮杂环状经取代吡咯、吡唑、咪唑、三唑和四唑衍生物
EP2240028B1 (fr) * 2007-12-06 2016-07-20 Intra-Cellular Therapies, Inc. Dérivés de Pyrazolopyrimidine-4,6-dione et leur utilisation pharmaceutique
DK2240490T3 (da) 2007-12-06 2013-12-16 Takeda Pharmaceutical Organiske forbindelser
AU2009322905A1 (en) 2008-12-06 2010-06-10 Intra-Cellular Therapies, Inc. Organic compounds
CN102238872A (zh) * 2008-12-06 2011-11-09 细胞内治疗公司 有机化合物
SG171776A1 (en) 2008-12-06 2011-07-28 Intra Cellular Therapies Inc Organic compounds
ES2638912T3 (es) 2008-12-06 2017-10-24 Intra-Cellular Therapies, Inc. Compuestos orgánicos
GEP20146046B (en) 2008-12-06 2014-02-25 Intracellular Therapies Inc Organic compounds
CA2740385A1 (fr) 2008-12-06 2010-06-10 Intra-Cellular Therapies, Inc. Composes organiques
EP2400970A4 (fr) 2009-02-25 2012-07-18 Intra Cellular Therapies Inc Inhibiteur de pde 1 pour troubles ophtalmiques
JP2012526810A (ja) 2009-05-13 2012-11-01 イントラ−セルラー・セラピーズ・インコーポレイテッド 有機化合物
SG178279A1 (en) 2009-08-05 2012-03-29 Intra Cellular Therapies Inc Novel regulatory proteins and inhibitors
CA2775840C (fr) 2009-10-01 2018-02-06 Metabolex, Inc. Sels de la tetrazol-1-yl-phenoxymethyl-thiazol-2-yl-piperidinyl-pyrimidine substituee
US20130065936A1 (en) * 2010-05-14 2013-03-14 The Regents Of The University Of California Modulation of bioactive epoxy-fatty acid levels by phosphodiesterase inhibitors
JP5879336B2 (ja) 2010-05-31 2016-03-08 イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． 有機化合物
JP5894148B2 (ja) 2010-05-31 2016-03-23 イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． 有機化合物
TW201206937A (en) 2010-05-31 2012-02-16 Intra Cellular Therapies Inc Organic compounds
WO2011153138A1 (fr) 2010-05-31 2011-12-08 Intra-Cellular Therapies, Inc. Composés organiques
WO2011156405A2 (fr) * 2010-06-07 2011-12-15 Novadel Pharma Inc. Formulations pour pulvérisation orale et méthodes d'administration de sildenafil
CN103037843A (zh) 2010-06-23 2013-04-10 麦它波莱克斯股份有限公司 5-乙基-2-{4-[4-(4-四唑-1-基-苯氧甲基)-噻唑-2-基]-哌啶-1-基}-嘧啶的组合物
JP6051210B2 (ja) 2011-06-10 2016-12-27 イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． 有機化合物
CN102276511A (zh) * 2011-06-20 2011-12-14 兰州博实生化科技有限责任公司 1-叔丁氧羰基-3-碘氮杂环丁烷的合成方法
US8449565B2 (en) 2011-07-21 2013-05-28 Francis Duhay Approaches to venous occlusion for embolus management
JP6549040B2 (ja) 2013-02-17 2019-07-24 イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． 新規使用
AU2014234990B2 (en) 2013-03-15 2017-11-16 Intra-Cellular Therapies, Inc. Organic compounds
US9545406B2 (en) 2013-03-15 2017-01-17 Intra-Cellular Therapies, Inc. Method of treating a CNS injury with a PDE1 inhibitor
RU2549459C2 (ru) * 2013-08-20 2015-04-27 Константин Александрович Корейба Способ лечения нейропатических трофических язв при синдроме диабетической стопы
JP6696904B2 (ja) 2014-01-08 2020-05-20 イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． 製剤および医薬組成物
WO2015196186A1 (fr) 2014-06-20 2015-12-23 Intra-Cellular Therapies, Inc. Composés organiques
US10285992B2 (en) 2014-08-07 2019-05-14 Intra-Cellular Therapies, Inc. Combinations of PDE1 inhibitors and NEP inhibitors and associated methods
ES2745819T3 (es) 2014-08-07 2020-03-03 Intra Cellular Therapies Inc Derivados de imidazo[1,2-a]-pirazolo[4,3-e]-pirimidin-4-ona con actividad inhibidora de la PDE1
US9546175B2 (en) 2014-08-07 2017-01-17 Intra-Cellular Therapies, Inc. Organic compounds
ES2857567T3 (es) 2014-09-17 2021-09-29 Intra Cellular Therapies Inc Derivados de 7,8-dihidro-[2h]-imidazo-[1,2-a]pirazolo[4,3-e]pirimidin-4(5h)-ona como inhibidores de fosfodiesterasa 1 (PDE1) para tratar enfermedades, trastornos o lesiones del sistema nervioso central (SNC)
BR112017012007B1 (pt) 2014-12-06 2022-11-01 Intra-Cellular Therapies, Inc Compostos orgânicos inibitórios de pde2, composições farmacêuticas compreendendo os ditos compostos e uso dos mesmos no tratamento de um distúrbio mediado por pde2
RU2702732C1 (ru) 2014-12-06 2019-10-10 Интра-Селлулар Терапиз, Инк. Органические соединения
US10813894B2 (en) 2015-02-20 2020-10-27 The Regents Of The University Of California Methods of inhibiting pain
EP3436083A4 (fr) 2016-03-28 2019-11-27 Intra-Cellular Therapies, Inc. Nouvelles compositions et méthodes
AU2017305392A1 (en) 2016-08-03 2019-02-21 Cymabay Therapeutics, Inc. Oxymethylene aryl compounds for treating inflammatory gastrointestinal diseases or gastrointestinal conditions
US20180072718A1 (en) 2016-09-09 2018-03-15 Incyte Corporation Pyrazolopyridine compounds and uses thereof
AR109596A1 (es) 2016-09-09 2018-12-26 Incyte Corp Compuestos pirazolopiridina y sus usos
AR109595A1 (es) 2016-09-09 2018-12-26 Incyte Corp Compuestos de pirazolopirimidina y usos de estos como inhibidores de hpk1
ES2906107T3 (es) 2016-09-12 2022-04-13 Intra Cellular Therapies Inc Usos novedosos
US20180228786A1 (en) 2017-02-15 2018-08-16 Incyte Corporation Pyrazolopyridine compounds and uses thereof
WO2019051199A1 (fr) 2017-09-08 2019-03-14 Incyte Corporation Composés de 6-cyano-indazole utilisés en tant que modulateurs de kinase 1 progénitrices hématopoïétiques (hpk1)
MX2017016930A (es) * 2017-12-19 2019-06-20 Malesil Research & Tech Llc Uso del maleato de sildenafil en el tratamiento de ulceras de pie diabetico.
JP7401442B2 (ja) 2018-01-31 2023-12-19 イントラ－セルラー・セラピーズ・インコーポレイテッド 新規使用
SI3755703T1 (sl) 2018-02-20 2022-11-30 Incyte Corporation N-(fenil)-2-(fenil)pirimidin-4-karboksamidni derivati in sorodne spojine kot zaviralci HPK1 za zravljenje raka
US10745388B2 (en) 2018-02-20 2020-08-18 Incyte Corporation Indazole compounds and uses thereof
WO2019164847A1 (fr) 2018-02-20 2019-08-29 Incyte Corporation Composés d'indazole et leurs utilisations
US11299473B2 (en) 2018-04-13 2022-04-12 Incyte Corporation Benzimidazole and indole compounds and uses thereof
US10899755B2 (en) 2018-08-08 2021-01-26 Incyte Corporation Benzothiazole compounds and uses thereof
JP7399968B2 (ja) 2018-09-25 2023-12-18 インサイト・コーポレイション Ａｌｋ２及び／またはｆｇｆｒ調節剤としてのピラゾロ［４，３－ｄ］ピリミジン化合物
JP2022543155A (ja) 2019-08-06 2022-10-07 インサイト・コーポレイション Ｈｐｋ１阻害剤の固体形態

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT100905A (pt) * 1991-09-30 1994-02-28 Eisai Co Ltd Compostos heterociclicos azotados biciclicos contendo aneis de benzeno, ciclo-hexano ou piridina e de pirimidina, piridina ou imidazol substituidos e composicoes farmaceuticas que os contem
WO1997024334A1 (fr) * 1995-12-28 1997-07-10 Fujisawa Pharmaceutical Co., Ltd. Derives du benzimidazole
KR100491282B1 (ko) * 1996-07-24 2005-05-24 워너-램버트 캄파니 엘엘씨 통증 치료용 이소부틸가바 및 그의 유도체
US6127418A (en) * 1997-08-20 2000-10-03 Warner-Lambert Company GABA analogs to prevent and treat gastrointestinal damage
JP3721077B2 (ja) * 1998-04-20 2005-11-30 ファイザー・インク 性的不全を治療するためのピラゾロピリミジノンｃＧＭＰＰＤＥ５阻害剤
US6331171B1 (en) * 1998-06-04 2001-12-18 Alcon Laboratories, Inc. Tip for a liquefracture handpiece
GB9823101D0 (en) * 1998-10-23 1998-12-16 Pfizer Ltd Pharmaceutically active compounds
GB9823103D0 (en) * 1998-10-23 1998-12-16 Pfizer Ltd Pharmaceutically active compounds
ES2205945T3 (es) * 1998-10-23 2004-05-01 Pfizer Inc. Pirazolopirimidinonas inhibidoras de gmpc pde5 para el tratamiento de disfunciones sexuales.
US6453237B1 (en) * 1999-04-23 2002-09-17 Global Locate, Inc. Method and apparatus for locating and providing services to mobile devices
US6411892B1 (en) * 2000-07-13 2002-06-25 Global Locate, Inc. Method and apparatus for locating mobile receivers using a wide area reference network for propagating ephemeris
IL137429A0 (en) * 1999-07-28 2001-07-24 Pfizer Prod Inc Methods and compsitions for treating diseases and conditions of the eye
WO2001026659A1 (fr) * 1999-10-12 2001-04-19 Lareida Juerg Produits pharmaceutiques utilises pour le traitement de neuropathies
US6560534B2 (en) * 2001-06-06 2003-05-06 Global Locate, Inc. Method and apparatus for distributing satellite tracking information
US7196660B2 (en) * 2000-11-17 2007-03-27 Global Locate, Inc Method and system for determining time in a satellite positioning system

Also Published As

Publication number Publication date
EP1440709A3 (fr) 2004-12-08
US20030162782A1 (en) 2003-08-28
JP2001122803A (ja) 2001-05-08
PE20010754A1 (es) 2001-07-18
ATE380049T1 (de) 2007-12-15
EP1129706A3 (fr) 2002-01-02
EP1440709A2 (fr) 2004-07-28
AU781550B2 (en) 2005-05-26
DE60037347T2 (de) 2008-11-27
AU6665000A (en) 2001-04-26
PT1440709E (pt) 2008-02-06
IL139073A0 (en) 2001-11-25
JP2003119131A (ja) 2003-04-23
EP1440709B1 (fr) 2007-12-05
IL152925A (en) 2010-04-15
CA2323839C (fr) 2008-03-18
HUP0004120A3 (en) 2003-11-28
CO5271711A1 (es) 2003-04-30
CY1107285T1 (el) 2012-11-21
KR20010051181A (ko) 2001-06-25
ES2295726T3 (es) 2008-04-16
HU0004120D0 (fr) 2001-01-29
US20040122010A1 (en) 2004-06-24
CA2323839A1 (fr) 2001-04-21
HUP0004120A2 (hu) 2002-11-28
EP1129706A2 (fr) 2001-09-05
DE60037347D1 (de) 2008-01-17

Similar Documents

Publication Publication Date Title
DK1440709T3 (da) Kombinationer, der omfatter cGMP PDE5 inhibitorer
BR0108750A (pt) Variantes da xilanase que apresentam sensibilidade alterada para inibidores da xilanase
GB2379798B (en) Light emitting diode and method for manufacturing the same
PL371515A1 (en) Hif hydroxylase inhibitors
DE60135387D1 (de) 7,9 substituierte tetracyclinverbindungen
ECSP045245A (es) N-aril-2-oxazolidinona-5-carboxamidas y sus derivados
BR0102059B1 (pt) segmento retentor para conjunto turbilhonador.
PT1350109E (pt) Marcador para patologias inflamatórias
WO2002014925A3 (fr) Structure de lampe a reflecteurs elliptiques pour irradier uniformement des surfaces de fibre optique et son procede d'utilisation
AU148080S (en) Spray pump head
WO2003024489A3 (fr) Combinaison d'un ains et d'un inhibiteur de pde4
AU148079S (en) Spray pump head
BR0307595A (pt) Uso de inibidores de pde5 tal como sildenafil no tratamento de sìndrome de ovário policìstico
TNSN06246A1 (fr) Nouvelle combinaison d'un agent antiemetique et d'un inhibiteur de l'encephalinase
PT941975E (pt) Cimento para injeccao contendo inibidores de corrosao
TR200705146T1 (tr) Monoamin Yükselmesinin Engellenmesi
MY138266A (en) Treatment of neuropathy
BR0210678A (pt) Carbamatos de 2-heterocìclicos-1,2-etanodióis
DE60215793D1 (de) Kombination eines gelatinasehemmers und eines anti-tumor-agent, und deren verwendung
WO2002049635A3 (fr) Utilisation d'acide 5-aminolevulinique pour assurer la prophylaxie de la restenose
ES1052291Y (es) Pieza para acera modular y acera modular que la incorpora.
ES1038279Y (es) Utensilio para el juego de dados.
ES1049152Y (es) Cañon ligero para armas.
RU2001103824A (ru) Средство для лечения острого мышьяковистого периодонтита
ECSP003855A (es) Inhibidores de fosfodiesterasa-4 8-arilquinolina sustituida